Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Endo Health Solutions Inc    ENDP

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Endo Pharmaceuticals Swings To 1Q Loss On Litigation Impacts

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/01/2012 | 02:13pm CEST

Endo Pharmaceuticals Holdings Inc.'s (>> Endo Pharmaceuticals Holdings Inc) swung to a first-quarter loss, mostly owing to a $110 million charge related to a 2010 litigation settlement, while the pharmaceutical company reported revenue grew with a boost from a recent acquisition.

Endo has seen its revenue rise in recent quarters, aided by acquisitions that expanded its generic-drug business and core painkiller franchise. But the related charges have hurt its bottom line of late.

First-quarter sales were expected to be affected by a temporary shutdown of a Novartis AG (NVS, Z.NOV) plant in Nebraska to address potential packaging errors. The plant manufactures some Endo products such as its Opana ER painkiller. In the latest period, Opana ER sales were down 4.2%. On Tuesday the company said Opana ER and Voltaren Gel now in steady supply.

Endo reported a loss of $87.3 million, or 75 cents a share, compared with a year-earlier profit of $55.8 million, or 46 cents a share. Excluding impacts from a 2010 litigation settlement with Impax Laboratories Inc. (IPXL), adjusted earnings were down at 87 cents from $1. The company in February expected earnings below 90 cents amid a temporary shutdown at the Novartis plant.

Revenue increased 23% to $691 million, with a boost from its American Medical Systems acquisition. Analysts polled by Thomson Reuters most recently projected $702 million.

Gross margin fell to 47.2% from 58.7%.

Sales of Lidoderm, which makes up the biggest chunk of Endo's top line, were up 11%.

Overall branded drug sales were down 3% while generics sales increased 8%.

Shares of Endo, which reaffirmed its 2012 guidance, closed Monday at $35.14 and were inactive premarket. The stock is down roughly 10% in the past year.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

Stocks mentioned in the article : Endo Pharmaceuticals Holdings Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ENDO HEALTH SOLUTIONS INC
09/23 Endo International CEO steps down, Campanelli named successor
08/09DJU.S. HOT STOCKS : Hot Stocks to Watch
08/03ENDO INTERNATIONAL PLC : half-yearly earnings release
07/21 ENDO INTERNATIONAL PLC : Lundin Law PC Announces Securities Class Action Lawsuit..
07/21 ENDO INTERNATIONAL PLC : DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Rem..
07/19 ENDO INTERNATIONAL PLC : INVESTOR NOTICE: Khang & Khang LLP Announces The Filing..
07/19 ENDO INTERNATIONAL PLC : DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Remi..
07/18 ENDO INTERNATIONAL PLC : UPCOMING DEADLINE: Lundin Law PC Announces Securities C..
07/18 ENDO INTERNATIONAL PLC : JULY 25, 2016 DEADLINE: Khang & Khang LLP Announces The..
07/13 ENDO INTERNATIONAL PLC : INVESTOR NOTICE: Lundin Law PC Announces Securities Cla..
More news
Sector news : Generic Pharmaceuticals
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/23 Endo International CEO steps down, Campanelli named successor
09/23DJSHIRE : Files 8K - Direct Or Off-Balance Sheet Financial Obligation
More sector news : Generic Pharmaceuticals
Advertisement
Financials ($)
Sales 2016 3 933 M
EBIT 2016 1 480 M
Net income 2016 402 M
Debt 2016 8 075 M
Yield 2016 -
P/E ratio 2016 25,42
P/E ratio 2017 10,19
EV / Sales 2016 3,38x
EV / Sales 2017 3,01x
Capitalization 5 211 M
More Financials
Technical analysis trends ENDO HEALTH SOLUT...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 29,0 $
Spread / Average Target 24%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Rajiv De Silva President, Chief Executive Officer & Director
Roger H. Kimmel Chairman
Robert J. Cobuzzi SVP-Operations, Research & Development Strategy
Suketu P. Upadhyay Chief Financial Officer & Executive Vice President
Susan T. Hall Chief Scientific Officer & Executive VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ENDO HEALTH SOLUTIONS ..5 211
SUN PHARMACEUTICAL IND..-5.02%28 165
OTSUKA HOLDINGS CO LTD5.19%25 163
BIOMARIN PHARMACEUTICA..-7.03%16 634
ONO PHARMACEUTICAL CO...-37.03%15 857
ASPEN PHARMACARE HOLDI..5.62%10 757
More Results